Cannabidiol-Cbd Medical Cannabis Studies

• View All (505)

5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid (2008)

Cannabidiol has the ability to kill glioma cells both in vitro and in vivo, independently of the stimulation of cannabinoid receptors. In this study performed in mice, the in vivo exposure of the tumor tissues with cannabidiol demonstrated a significant decrease in the activity and content of 5-lipoxygenase (LOX, 40%) and its final pipeline, leukotriene B4 (25 %). It is demonstrated in this study that cannabidiol exerts its antitumor effects through the modulation of the LOX pathway and the endocannabinoid system. This suggests a possible interaction of these routes in the control of tumor growth. View study
An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse (Documento PDF da�ado)

View study
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies (2017)

This survey seeks to expand the survey previously done by Bergamaschi et al. in 2011 on the safety and side effects of cannabidiol (CBD), as well as updating literature. This paper focuses on clinical studies and the possible interactions of the CBD with other medications. View study
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro (2007)

It has been shown that Cannabidiol, a non-psychoactive component of cannabis, has low affinity for cannabinoid receptors CB1 and CB2, and in this study the first evidence is shown that it can also show the inverse agonism of the CB2 receptor. What can contribute to its documented anti-inflammatory properties. View study
Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor (no year)

This study was made based on the hypothesis that cannabidiol can inhibit the activity of cannabinoid agonists through the negative allosteric modulation of CB1. The results of this study showed that cannabidiol behaved as a non-competitive allosteric modulator of CB1.The allosteric modulation, together with the effects that are not CB1, can show the in vivo effects of cannabidiol. The allosteric modulators of CB1 have the potential to treat the central nervous system and peripheral disorders, while avoiding the adverse effects associated with orthosteric agonism or CB1 antagonism. View study
Cannabidiol: Promise and Pitfalls (2014)

This review points out a bit of the basic science theory behind the use of CBD, summarizes the published data on its clinical use for epilepsy and exposes the problems related to the use of CBD products at present. View study
Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid (2016)

This research seeks to identify the psychoactive degradants of cannabidiol in simulated gastric and physiological fluids. It was concluded that the simulated gastric fluid SGF converts cannabidiol (CBD) into the psychoactive components D9 -THC and D8 -THC. View study
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent (2011)

View study